story of the week
Long-Term Efficacy, Safety, and Neurotolerability of the MATRix Regimen Followed by Autologous Transplant in Primary CNS Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
Leukemia 2022 May 13;[EPub Ahead of Print], AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox, E Schorb, C Celico, M Falautano, A Nonis, P La Rosée, M Binder, A Fabbri, F Ilariucci, M Krampera, A Roth, C Hemmaway, PW Johnson, KM Linton, T Pukrop, JS Gørløv, M Balzarotti, G Hess, U Keller, S Stilgenbauer, J Panse, A Tucci, L Orsucci, F Pisani, M Zanni, SW Krause, HJ Schmoll, B Hertenstein, M Rummel, J Smith, L Thurner, G Cabras, E Pennese, M Ponzoni, M Deckert, LS Politi, J Finke, A Ferranti, K Cozens, E Burger, N Ielmini, F Cavalli, E Zucca, G IllerhausFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.